Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price rose 6.9% during mid-day trading on Thursday . The company traded as high as GBX 5.96 ($0.08) and last traded at GBX 5.88 ($0.08). Approximately 591,028 shares changed hands during trading, a decline of 15% from the average daily volume of 695,330 shares. The stock had previously closed at GBX 5.50 ($0.07).
Allergy Therapeutics Stock Performance
The company has a market cap of £248.04 million, a PE ratio of -98.00, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22. The business has a fifty day moving average of GBX 5.05 and a 200-day moving average of GBX 4.84.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Read More
- Five stocks we like better than Allergy Therapeutics
- How to buy stock: A step-by-step guide for beginners
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- P/E Ratio Calculation: How to Assess Stocks
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Why Are Stock Sectors Important to Successful Investing?
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
